SOLV vs HOLX

For growth investors, Hologic, Inc.

(HOLX) is the stronger pick with 1. 7% revenue growth year-over-year, versus 0. 9% for Solventum Corporation (SOLV). Solventum Corporation (SOLV) offers the better valuation at 8. 1x trailing P/E (11. 1x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.

1x versus Hologic, Inc. at 30. 5x. On forward P/E, Solventum Corporation is actually cheaper at 11. 1x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -10. 4% for Solventum Corporation (SOLV). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus SOLV's -10. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Solventum Corporation's 1. 05β — meaning SOLV is approximately 156% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 100% for Solventum Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hologic, Inc.

(HOLX) is pulling ahead at 1. 7% versus 0. 9% for Solventum Corporation (SOLV). On earnings-per-share growth, the picture is similar: Solventum Corporation grew EPS 221. 7% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, SOLV leads at 0. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Solventum Corporation (SOLV) is the more profitable company, earning 18.

7% net margin versus 13. 8% for Hologic, Inc. — meaning it keeps 18. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26. 2% versus 17. 4% for HOLX. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Solventum Corporation (SOLV) trades at 11.

1x forward P/E versus 17. 2x for Hologic, Inc. — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SOLV: 36. 5% to $97. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, SOLV: -10. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SOLV is a mid-cap deep-value stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.